← Back to Search

Chemotherapy Agent

Sequential Chemotherapy and Lenalidomide + Rituximab and Lenalidomide Maintenance for Mantle Cell Lymphoma

Phase 2
Waitlist Available
Led By Anita Kumar, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial is testing a new combination of drugs to treat lymphoma. Researchers want to see if it is effective and safe.

Eligible Conditions
  • Mantle Cell Lymphoma
  • Untreated

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
3-year progression-free survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: ChemotherapyExperimental Treatment3 Interventions
Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenalidomide
2005
Completed Phase 3
~1480
R-CHOP
2015
Completed Phase 2
~210
high-dose cytarabine (HIDAC)
2015
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Celgene CorporationIndustry Sponsor
444 Previous Clinical Trials
58,187 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,934 Previous Clinical Trials
588,761 Total Patients Enrolled
Anita Kumar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
754 Total Patients Enrolled

Media Library

HIDAC (Chemotherapy Agent) Clinical Trial Eligibility Overview. Trial Name: NCT02633137 — Phase 2
Mantle Cell Lymphoma Research Study Groups: Chemotherapy
Mantle Cell Lymphoma Clinical Trial 2023: HIDAC Highlights & Side Effects. Trial Name: NCT02633137 — Phase 2
HIDAC (Chemotherapy Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02633137 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other research studies have looked at Lenalidomide's effects?

"The first study for lenalidomide was completed in 1993 at the National Institutes of Health Clinical Center. As of now, a total of 2924 trials have been completed with 1824 currently active. A large number these current experiments are based out of Middletown, New york."

Answered by AI

Can people with the target condition participate in the trial at this time?

"This study is not recruiting patients at this time, according to the latest update on February 17th, 2022. If you are interested in participating in other trials, there are presently 1763 studies actively looking for participants with lymphoma and 1824 trials for Lenalidomide admitting patients."

Answered by AI

What are the primary conditions that Lenalidomide is used to manage?

"Lenalidomide is primarily used as a leukemia treatment, but it can also be effective against ophthalmia, sympathetic, and certain types of lung cancer."

Answered by AI

Is this clinical trial widely available in city?

"There are seven locations currently running this clinical trial: Memorial Sloan Kettering Monmouth in Middletown, Memorial Sloan Kettering Westchester in Harrison, and Memorial Sloan Kettering Commack in Commack. There are also four other sites."

Answered by AI

How many people are agreeing to participate in this research?

"No, this trial is no longer recruiting patients. Originally posted on December 14th 2015, the last update was on February 17th 2022. There are many other trials currently underway though: as of right now, there are 1763 lymphoma trials and 1824 Lenalidomide trials actively enrolling participants."

Answered by AI

What is the official stance of the FDA on Lenalidomide?

"Lenalidomide's safety was given a score of 2 because, while there is some evidence backing its safety, none supports its efficacy."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
2015. "Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02633137.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top